Due to a system-wide technology update, we are experiencing extremely high call volume. We appreciate your patience with our operators during this time. Thank you for choosing Fox Chase Cancer Center.
New Information About Head and Neck Cancer Outlined in Molecular Determinants of Head and Neck Cancer, 2nd Edition
PHILADELPHIA (July 11, 2018) – Fox Chase Cancer Center is pleased to announce the publication of Molecular Determinants of Head and Neck Cancer, 2nd Edition, edited by Erica Golemis, PhD, deputy chief science officer at Fox Chase Cancer Center, and Barbara Burtness, MD, Disease Aligned Research Team Leader of the Head and Neck Cancers Program at Yale Cancer Center.
This new edition informs readers of significant advances in the understanding of this disease and the new therapies that have become available, with a focus on novel drug targets to improve the outcomes of head and neck squamous cell carcinomas (HNSCC). HNSCCs arise in the oral cavity, pharynx, and larynx; approximately 600,000 new cases will be diagnosed worldwide in 2018.
The book specifically addresses the biology and treatment of different subtypes of HNSCC, including the rapidly growing class of human papillomavirus (HPV) – driven HNSCC. Along with Golemis and Burtness, several current and former Fox Chase faculty members contributed to this book, including Jeffrey Liu, Camille Ragin, Suraj Peri, Andrew J. Andrews, Ranee Mehra, and Ilya G. Serebriiskii.
“In the four years, since the original book was published, we have seen considerable advances in understanding disease mechanisms, and developing new treatments, including promising new immunotherapies,” said Golemis. “The key to success in treating HNSCC comes from our ability to translate bench research into clinical trials, which is emphasized in this updated edition.”
The second edition is available for purchase now.
Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence five consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.
For more information, call 888-369-2427